-
摘要: 亮氨酸拉链肿瘤抑制因子2（leucine zipper tumor suppressor 2，LZTS2）是一种新的肿瘤抑制基因，近年受到越来越多的关注。目前许多研究表明，LZTS2与多种肿瘤的发生和细胞异常增殖等多个环节密切相关，是重要的候选肿瘤抑制基因，可为肿瘤的治疗提供新的思路。
-
关键词:
- 亮氨酸拉链肿瘤抑制因子2 /
- 抑癌基因 /
- 肿瘤
Abstract: Leucine zipper tumor suppressor 2 (LZTS2) is a novel tumor suppressor gene that has been increasingly recognized in recent years. Currently, many studies illustrate that LZTS2 gene, the important candidate tumor suppressor gene, is already involved in the inhibition of tumorigenesis and aberrant proliferation of tumor cells, and other functions of tumor cells. Information from these studies can contribute to the formulation of new strategies for the treatment of tumors.-
Key words:
- leucine zipper tumor suppressor 2 /
- tumor suppressor gene /
- cancer
-
[1] Daniel TJ, Richard L, Suk HL, et al. Deletion of leucine zipper tumor suppressor 2 (Lzts2) increases susceptibility to tumor development[J]. J Biol Chem, 2013, 288(6):3727-3738. doi: 10.1074/jbc.M112.417568 [2] Teufel A, Weinmann A, Galle PR, et al. In silico characterization of LZTS3, a potential tumor suppressor[J]. Oncol Rep, 2005, 14(2): 547-551. http://cn.bing.com/academic/profile?id=985f9fd8004e701a6b4d60ed7a0bafbc&encoded=0&v=paper_preview&mkt=zh-cn [3] Yofre CA, Timothy CT, Jorge LS, et al. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3[J]. Oncogene, 2001, 20 (46):6707-6717. doi: 10.1038/sj.onc.1204866 [4] Cui QZ, Tang ZP, Zhang XP, et al. Leucine zipper tumor suppressor 2 inhibits cell proliferation and regulates Lef/Tcf-dependent transcription through Akt/GSK3β signaling pathway in lung cancer [J]. J Histochem Cytochem, 2013, 61(9):659-670. doi: 10.1369/0022155413495875 [5] Jong MK, Ji SS, Hyun HC, et al. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor[J]. Mol Cell Biochem, 2011, 346(1-2):125-136. doi: 10.1007/s11010-010-0599-y [6] Hyun HC, Hye JJ, Ji SS, et al. Crossregulation of β-catenin/Tcf pathway by NF-κ B is mediatedby lzts 2 in human adipose tissue-derived mesenchymal stem cells[J]. Biochim Biophys Acta, 2008, 1783(3):419-428. [7] Phin S, Moore MW, Cotter PD. Genomic rearrangements of PTEN in prostate cancer[J]. Front Oncol, 2013, 3:240. http://cn.bing.com/academic/profile?id=ddb1cc407510ddac34f99d927c8694a8&encoded=0&v=paper_preview&mkt=zh-cn [8] Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy[J]. Clin Cancer Res, 2014, 20(12):3057-3063. doi: 10.1158/1078-0432.CCR-12-3680 [9] Olar A, He D, Florentin D, et al. Biological correlates of prostate cancer perineural invasion diameter[J]. Hum Pathol, 2014, 45 (7):1365-1369. doi: 10.1016/j.humpath.2014.02.011 [10] Al Bashir S, Alshalalfa M, Hegazy SA, et al. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis[J]. J Hematol Oncol, 2014, 7(7):1-11. http://cn.bing.com/academic/profile?id=df0cf377b71ca588e89208a2dbb2f252&encoded=0&v=paper_preview&mkt=zh-cn [11] Yue S, Li J, Lee SY, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K / AKT activation underlies humanprostate cancer aggressiveness[J]. Cell Metab, 2014, 19(3):393-406. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969850/ [12] Choy E, MacConaill LE, Cote GM, et al. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1[J]. PLoS One, 2014, 9(7):e101283. doi: 10.1371/journal.pone.0101283 [13] Iida M, Anna CH, Gaskin ND, et al. The putative tumor suppressor Tsc-22 is downregulated early in chemically induced hepatocarcinogenesis and may be a suppressor of Gadd45b[J]. Toxicol Sci, 2007, 99(1):43-50. http://cn.bing.com/academic/profile?id=cf42c9e9b183b00deb8994fa6d2368cb&encoded=0&v=paper_preview&mkt=zh-cn [14] Seeger-Nukpezah T, Little JL, Serzhanova V, et al. Cilia and cilia-associated proteins in cancer[J]. Drug Discov Today Dis Mech, 2013, 10(3-4):e135-e142. doi: 10.1016/j.ddmec.2013.03.004 [15] MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases[J]. Dev Cell, 2009, 17(1):9-26. doi: 10.1016/j.devcel.2009.06.016 [16] Moyes LH, McEwan H, Radulescu S, et al. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus [J]. J Pathol, 2012, 228(1):99-112. http://cn.bing.com/academic/profile?id=1953363531f1d7bba2fe1e9d95d5cf20&encoded=0&v=paper_preview&mkt=zh-cn [17] He M, Li Y, Zhang L, et al. Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway inmedulloblastoma[J]. Oncol Rep, 2014, 32(1):173-180. https://www.researchgate.net/publication/262610318_Curcumin_suppresses_cell_proliferation_through_inhibition_of_the_Wnt-catenin_signaling_pathway_in_medulloblastoma [18] Gregory T, Tzu-Huey L, Lynn L, et al. LZTS2 Is a Novel β-Catenin Interacting Protein and Regulates the Nuclear Export of β-Catenin[J]. Mol Cell Biol, 2006, 26(23):8857-8867. doi: 10.1128/MCB.01031-06 [19] Bradford JW, Baldwin AS. IKK/Nuclear Factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment[J]. Adv Cancer Res, 2014, 121:125-145. doi: 10.1016/B978-0-12-800249-0.00003-2 [20] Block MS, Charbonneau B, Vierkant RA, et al. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer [J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(7):1421-1427. doi: 10.1158/1055-9965.EPI-13-0962 [21] Liu H, Yang J, Yuan Y, et al. Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cellcarcinoma cells[J]. BMC Cancer, 2014, 17 (14):98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930545/ [22] Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship[J]. Mol Cell Biochem, 2010, 336(1-2): 25-37. doi: 10.1007/s11010-009-0267-2 [23] Uno M, Saitoh Y, Mochida K, et al. NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression[J]. PLoS One, 2014, 9(2): e88347. doi: 10.1371/journal.pone.0088347 [24] Baldoni S, Sportoletti P, Del Papa B, et al. NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion[J]. Int J Hematol, 2013, 98(2):153-157. doi: 10.1007/s12185-013-1368-y [25] Wang X, Adhikari N, Li Q, et al. The role of [beta]-transducin repeat containing protein ([beta]-TrCP) in the regulation of NF-[kappa]B in vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2004, 24(1):85-90. doi: 10.1161/01.ATV.0000104012.40720.c4 [26] Hyun HC, Ji SS, Yu JM, et al. Differential effect of NF- κB activity on β-catenin/Tcf pathway in various cancer cells[J]. FEBS Lett, 2008, 582(5):616-622. doi: 10.1016/j.febslet.2008.01.029 [27] Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies[J]. Int J Hematol, 2011, 93(3):294-300. doi: 10.1007/s12185-011-0799-6 [28] Sun SC, Chang JH, Jin J. Regulation of nuclear factor-kB in autoimmunity[J]. Trends Immunol, 2013 June, 34(6):282-289. https://mdanderson.elsevierpure.com/en/publications/regulation-of-nuclear-factor-%ce%bab-in-autoimmunity [29] Paul S, Schaefer BC. A new look at T cell receptor signaling to nuclear factor-Kb[J]. Trends Immunol, 2013, 34(6):269-281. doi: 10.1016/j.it.2013.02.002 [30] Gattinoni L, Ji Y, Restifo NP. Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy[J]. Clin Cancer Res, 2010, 16(19):4695-4701. doi: 10.1158/1078-0432.CCR-10-0356 [31] Tomonori Y, Yasufumi G, Kenji K, et al. Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells[J]. J Immunol, 2012, 189(5): 2110-2117. doi: 10.4049/jimmunol.1102282 [32] Notani D, Gottimukkala KP, Jayani RS, et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner[J]. PLoS Biol, 2010, 8:e1000296. doi: 10.1371/journal.pbio.1000296 [33] Zhou X, Yu S, Zhao DM, et al. Differentiation and persistence of memory CD8 + T cells depe nd on T cell factor 1[J]. Immunity, 2010, 32:229-240. https://www.researchgate.net/publication/45798260_Differentiation_and_Persistence_of_Memory_CD8_T_Cells_Depend_on_T_Cell_Factor_1?ev=auth_pub [34] Zhao J, Yue W, Zhu MJ, et al. AMP-activated protein kinase(AMPK) cross-talks with canoni cal Wnt signaling via phosphorylation of beta- catenin at Ser 552[J]. Biochem Biophys Res Commun, 2010, 395: 146-151. doi: 10.1016/j.bbrc.2010.03.161 [35] Liang J, Lin C, Hu F, et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis[J]. Am J Epidemiol, 2013, 177(11):1169-1179. doi: 10.1093/aje/kws382 [36] Meguerditchian AN, Bullard Dunn K. Biomarkers and targeted therapeutics in colorectal cancer[J]. Surg Oncol Clin N Am, 2013, 22(4): 841-855. doi: 10.1016/j.soc.2013.07.002 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 42
- HTML全文浏览量: 7
- PDF下载量: 0
- 被引次数: 0
